The countries that temporarily disqualify you from donating blood depend on which blood service you’re donating to, but the broad categories are consistent worldwide: regions where malaria is transmitted, countries historically linked to mad cow disease (particularly the United Kingdom and parts of Europe), and areas where parasitic infections like Chagas disease are endemic. The specific deferral periods, the exact list of flagged countries, and whether testing can substitute for a waiting period all vary by country and sometimes by individual blood collection agency. What stays constant is the underlying logic: certain infections can hide in your blood for weeks, months, or even years without making you feel sick, and a single contaminated donation can be fatal for the recipient.
Malaria Is the Biggest Reason for Travel-Related Deferrals
Malaria accounts for more travel-related blood donation deferrals than any other disease. The parasite, carried by mosquitoes across large swaths of sub-Saharan Africa, South and Southeast Asia, Central and South America, and parts of the Middle East, can persist in a donor’s bloodstream at levels too low to cause symptoms but high enough to infect a transfusion recipient. Blood banks in non-endemic countries treat this as a serious concern because submicroscopic infections can occur even in areas with relatively low transmission rates.1PubMed Central. Asymptomatic infections in blood donors harbouring Plasmodium: an invisible risk detected by molecular and serological tools
In the United States, the traditional rule was straightforward: if you traveled to a malaria-endemic area, you had to wait 12 months before donating. If you previously lived in one of those areas, the wait stretched to three years. The American Red Cross and most other U.S. collection agencies still use geography-based deferral, though they’ve begun exploring alternatives. The list of affected countries is long and essentially mirrors the CDC’s malaria-risk map, covering most of sub-Saharan Africa, large parts of India, much of Southeast Asia, and pockets of Central and South America and Oceania.
Other countries take slightly different approaches. Canada, for example, has been working toward replacing geography-based deferrals with direct molecular testing of donated blood for the malaria parasite. New nucleic acid testing (NAT) technology can detect the parasite’s genetic material at extremely low concentrations, and confirmatory assays are being validated to catch reactive donations before they reach patients.2PubMed. Development and validation of a pan-Plasmodium molecular assay as a confirmatory method for blood donor screening Canadian researchers have demonstrated detection thresholds more than a hundred times more sensitive than conventional diagnostic tests, identifying parasites at levels as low as about 13 infected red blood cells per milliliter of blood.3PubMed. Donor management implications for high-sensitivity detection of low-level malaria parasitemia in blood donor screening If this kind of screening becomes standard, many travel deferrals could eventually be shortened or eliminated, because the test catches what the waiting period is designed to prevent.
The United Kingdom and Mad Cow Disease
One of the most widely known travel deferrals has nothing to do with mosquitoes. Since the late 1990s, the U.S. Food and Drug Administration has barred blood donation from anyone who spent a cumulative six months or more in the United Kingdom between 1980 and 1996, when the bovine spongiform encephalopathy (BSE) crisis was at its peak. The concern is variant Creutzfeldt-Jakob disease (vCJD), a fatal brain disease caused by misfolded proteins called prions that can be transmitted through contaminated blood. The FDA later extended the ban to cover people who spent six months or more in the UK at any time since 1980, a policy shift expected to reduce the national blood supply by roughly 2.2%.4PubMed Central. FDA bans blood donation by people who have lived in UK
The deferral wasn’t limited to the UK. France, Ireland, and several other European countries where BSE cases were identified also trigger deferrals under U.S. rules, though the thresholds differ. For much of Europe, the cutoff was five years of cumulative time spent on the continent between 1980 and 2001. Anyone who received a blood transfusion in the UK or France during those years is permanently deferred in the United States, regardless of how long they stayed.
What makes the vCJD deferral unusual is that there’s no blood test for prions that works reliably enough for donor screening. Unlike malaria, where molecular testing may eventually replace geographic deferrals, vCJD policies are stuck relying on travel history because the diagnostic technology doesn’t exist yet. The number of actual vCJD cases worldwide has been small (a few hundred total), and only a handful were linked to blood transfusion. But prion diseases are invariably fatal and have no treatment, so blood agencies err heavily on the side of caution. Many donors who lived in or were stationed in Europe during the 1980s and 1990s remain permanently ineligible in the U.S., even decades later.
It’s worth noting that the UK itself does not defer its own residents for this risk. The policy is specific to non-endemic countries trying to keep prion-contaminated blood out of their supply. If you’re donating blood in England, your time spent living in England is obviously not grounds for deferral. The same asymmetry applies to malaria rules: countries where malaria is endemic don’t defer travelers who visited malaria zones, because their entire donor pool would be disqualified.
Chagas Disease and Latin America
Chagas disease, caused by the parasite Trypanosoma cruzi and transmitted by triatomine bugs (sometimes called “kissing bugs”), creates a different kind of blood safety challenge. The parasite is endemic across much of Central and South America, and infection can remain silent for decades while slowly damaging the heart and digestive system. For blood banks, the danger is that an infected donor may feel perfectly healthy and have no idea they’re carrying the parasite.
How blood services handle Chagas risk varies widely. An international survey of blood services in non-endemic regions found that about 43% tested donors for T. cruzi, and most of those used travel history or length of stay in an endemic area as part of their screening algorithm.5PubMed. Deferral of blood donors who have ever stayed in a Trypanosoma cruzi endemic area: An international survey Some countries defer anyone who has ever lived in an endemic region for a certain period. Others test the blood directly and allow donation if the test is negative. In the U.S., universal antibody testing of donated blood has largely replaced geography-based deferrals for Chagas, meaning you generally won’t be turned away just because you visited Bolivia or Brazil. But in countries that don’t test every donation, a trip to endemic Latin American regions can still trigger a deferral.
The survey data underscore how uncommon actual positive findings are among travelers specifically: over decades of observation across multiple blood services, only two confirmed-positive donations came from donors whose sole risk factor was having stayed in an endemic area, while nearly 300 confirmed positives came from donors with additional risk factors like birth in an endemic country or a mother born in one.5PubMed. Deferral of blood donors who have ever stayed in a Trypanosoma cruzi endemic area: An international survey This suggests that short-term travel to Latin America poses a very small Chagas risk compared to long-term residence, but blood services still screen for it because the consequences of missing a positive donation are severe.
Dengue, Zika, and Other Mosquito-Borne Viruses
Malaria isn’t the only mosquito-borne infection that blood banks worry about. Dengue fever, Zika virus, and chikungunya are all transmitted by Aedes mosquitoes and can circulate in a donor’s blood before symptoms appear. A person bitten by an infected mosquito in Thailand or the Caribbean might feel fine when they return home and show up to donate blood, but their blood could transmit the virus to a recipient.
Dengue has been flagged as a growing concern for blood supply safety, particularly as the geographic range of the virus expands and more travelers are exposed. Researchers have noted that the risk of transfusion-transmitted dengue from asymptomatic viremic donors is likely to increase as the disease spreads, and that more deferrals will be needed in response.6PubMed Central. Is dengue a threat to the blood supply? Most blood services currently impose a short deferral, typically 14 to 28 days, after travel to areas with active dengue outbreaks, or after confirmed or suspected dengue infection. Zika triggers similar short-term deferrals, often 28 days after leaving an affected area or after symptoms resolve, though some agencies have moved to testing donated blood directly for Zika RNA instead of relying on deferrals.
West Nile virus operates slightly differently because it is now endemic in parts of North America and Europe, not just a travel-imported risk. Blood services in affected countries screen donations seasonally using NAT rather than deferring every donor who spent time outdoors during mosquito season. Canadian blood donor screening data from 2018 to 2023 found no West Nile-positive donors among those who had recently traveled outside the country during the off-season, confirming that the risk is primarily domestic rather than imported.7PubMed Central. West Nile Virus positivity amongst Canadian blood donors and effectiveness of off‐season screening In practice, this means West Nile rarely triggers travel deferrals. Instead, it’s handled through routine testing of the blood supply in countries where the virus circulates.
Less Common Deferrals You Might Not Expect
Beyond the big three categories of malaria, vCJD, and Chagas, several other infections tied to specific geographic regions can affect your eligibility to donate.
Babesiosis, caused by tick-borne parasites in the genus Babesia, is a major concern for the U.S. blood supply because Babesia microti is endemic in parts of the northeastern and upper midwestern United States. The parasite infects red blood cells and can persist for months or years without causing symptoms, meaning healthy-seeming donors can unknowingly carry it.8PubMed Central. Preventing Transfusion-Transmitted Babesiosis This is mainly a domestic U.S. concern rather than a travel-based deferral for international visitors, but it illustrates how even within a country, geography can determine whether your blood is considered safe. The FDA now recommends testing or pathogen reduction for donations collected in endemic states.
Leishmaniasis, a parasitic disease transmitted by sandflies in parts of the Middle East, North Africa, South Asia, and Latin America, triggers deferrals in some countries. Israel, for instance, does not accept blood from people with multiple active skin lesions from cutaneous leishmaniasis due to the theoretical risk of parasites being present in the bloodstream. However, research has called this policy into question: a study of patients with active or recent cutaneous leishmaniasis caused by common Old World species found no detectable parasites in their blood, suggesting that the exclusion may be more conservative than necessary.9PubMed Central. Failure to Detect Leishmania in the Blood of Patients with Old-World Cutaneous Leishmaniasis: Implications for Blood Donation
Human T-lymphotropic virus type 1 (HTLV-1) is another infection that shapes blood donation policy in relation to certain regions. Sub-Saharan Africa, parts of the Caribbean, Japan, and some areas of South America have higher rates of HTLV-1, which can cause a rare leukemia and a progressive neurological disease. A study of blood donors in southeastern Gabon found an HTLV-1 seroprevalence of about 2% at the donor level, with a history of prior blood transfusion being the strongest risk factor for infection.10PubMed Central. High prevalence of HTLV-1 among blood donors in southeastern Gabon (Central Africa): a major challenge for transfusion safety in a semi-rural area Many blood services in non-endemic countries test all donations for HTLV rather than relying on travel deferrals, but in some settings, travel to or birth in a high-prevalence area can still trigger additional screening or deferral.
Why Rules Differ So Much Between Countries
One of the most frustrating things for frequent travelers is that blood donation rules aren’t standardized globally. You might be eligible to donate in the UK after a trip to Kenya but face a 12-month wait in the United States for the same trip. The reasons for these differences come down to a few practical factors.
First, each country’s blood service makes its own risk calculations based on its specific donor pool. A country with a large diaspora from malaria-endemic regions has a different risk profile than one where very few donors have travel exposure. Second, available technology matters: countries that have adopted NAT screening for malaria parasites can afford to shorten or eliminate geographic deferrals because they’re catching infected blood directly. Countries still relying on antibody tests or questionnaire-based screening have to keep the waiting periods longer. Third, there’s always a tension between safety and supply. Every deferral rule removes potential donors from the pool, and blood shortages cost lives too.
Canada illustrated this trade-off clearly when it revised its malaria deferral rules for travel to Mexico. Mexico’s malaria risk is concentrated in a few rural states, yet the previous policy deferred any donor who had visited anywhere in the country. After the policy was updated to reflect the actual geographic distribution of malaria within Mexico, roughly 36,000 fewer donations were lost per year, a 37% reduction in deferrals from the previous year.11PubMed Central. Impact of changes to policy for Mexican risk travel on Canadian blood donor deferrals The change recovered a substantial volume of blood without meaningfully increasing infection risk, because the vast majority of those deferred donors had visited parts of Mexico where malaria doesn’t circulate.
This kind of policy refinement is happening in multiple countries. The general trend is toward more granular, region-specific rules rather than blanket country-level deferrals, and toward laboratory testing that can replace or shorten waiting periods. But progress is uneven, and many blood services still rely on broad geographic categories because implementing and validating new testing is expensive and slow.
How Climate Change Is Redrawing the Map
The list of countries that trigger blood donation deferrals isn’t static. As climate change pushes the geographic range of disease-carrying mosquitoes and ticks into new areas, the risk map is expanding. West Nile virus offers a concrete example: climate projections show a higher probability of WNV infection in areas at the edges of current transmission zones in Europe, including parts of Croatia and Turkey, with further expansion expected by mid-century.12PubMed Central. Climate change projections of West Nile virus infections in Europe: implications for blood safety practices
Dengue has already moved into regions where it was previously absent, including southern Europe and the southern United States. Malaria transmission boundaries are shifting in parts of East Africa and South Asia. For blood services, this means that countries or regions currently considered low-risk may need to be added to deferral lists in the coming decades, and seasonal screening windows may need to be extended. It also means that the already-complex patchwork of country-specific rules will get more complicated, not less, unless universal laboratory screening of donated blood becomes the norm.
What to Do Before You Travel
If you’re a regular blood donor and you have a trip planned, the practical steps are simple but worth taking. Check your blood service’s website for their specific travel deferral list before you go. In the U.S., the American Red Cross maintains an online eligibility tool where you can enter your travel dates and destinations. NHS Blood and Transplant in the UK, Canadian Blood Services in Canada, and the Australian Red Cross Lifeblood service all have similar tools. The exact deferral period depends on where you went, how long you stayed, and what diseases are active in that area at the time.
A few practical points to keep in mind:
- Airport layovers count: Some blood services consider even brief stops in endemic countries as triggering a deferral, though policies vary on minimum duration.
- Cruise ship ports: Docking in a malaria-endemic country, even for a day excursion, can start the deferral clock.
- Military deployment: Service members stationed in endemic regions often face the longest deferrals, particularly for malaria and vCJD.
- Rules change: Outbreak status updates can add or remove countries from deferral lists on short notice, particularly for diseases like Zika and dengue that flare unpredictably.
If you’ve been deferred after travel and are unsure whether you’re eligible again, call your blood service directly rather than guessing. The questionnaire you fill out at the donation center will catch most issues, but staff can clarify edge cases, especially for complex travel itineraries or countries where only certain regions carry risk. The deferral isn’t a judgment about your health; it’s a safeguard for recipients who may have compromised immune systems and no ability to fight off an infection that your body handled without you even noticing.